Methods of treating joint diseases, disorders, and conditions with tissue inhibitors of matrix metalloproteinases

1. A method of treating a joint disease, disorder, or condition in a subject in need thereof, the method comprising injecting a composition comprising an amniotic fluid comprising a therapeutically effective amount of tissue inhibitors of matrix metalloproteinases (TIMPs) into the joint of the subject, thereby treating the joint disease, disorder, or condition, wherein the amniotic fluid is obtained from a pregnant female donor between week 28 and week 37 of gestation, wherein particulate matter in the amniotic fluid is substantially eliminated in the amniotic fluid prior to the composition being injected into the joint, and wherein a concentration of the TIMPs in a sample of the amniotic fluid is determined prior to injecting the composition into the joint.

2. The method according to claim 1 , wherein the joint is selected from the group consisting of a synovial joint and a cartilaginous joint.

3. The method according to claim 1 , wherein the joint disease, disorder, or condition is associated with degradation of cartilage by proteases.

4. The method according to claim 3 , wherein the proteases comprise matrix metalloproteinases.

5. The method according to claim 1 , wherein the joint disease, disorder, or condition is selected from the group consisting of joint inflammation, osteoarthritis, rheumatoid arthritis, and chondromalacia patellae.

6. The method according to claim 1 , wherein the joint is a synovial joint.

7. The method according to claim 1 , wherein the joint is a knee joint.

8. The method according to claim 1 , wherein the amniotic fluid is obtained from the pregnant female donor during a Caesarean section procedure.

9. The method according to claim 1 , including determining that the amniotic fluid does not contain a therapeutically effective amount of the TIMPs and removing water from the amniotic fluid to enrich the amniotic fluid for endogenous TIMPs whereby the enriched amniotic fluid includes the therapeutically effective amount of the TIMPs.

10. The method according to claim 1 , wherein the joint disease, disorder, or condition is osteoarthritis of a synovial joint, wherein the osteoarthritis is associated with degradation of articular cartilage by proteases, and the composition is injected into the synovial joint.

11. The method according to claim 10 , wherein the proteases are matrix metalloproteinases.

12. The method according to claim 10 , wherein the synovial joint is a knee joint, wrist joint, shoulder joint, hip joint, elbow joint, or neck joint.

13. The method according to claim 12 , wherein the synovial joint is a knee joint.

14. The method according to claim 1 , including determining that the amniotic fluid does not contain a therapeutically effective amount of the TIMPs and increasing the TIMPs concentration in the amniotic fluid whereby the enriched amniotic fluid includes the therapeutically effective amount of the TIMPs.

15. The method according to claim 1 , wherein the amniotic fluid is processed by removing water to enrich the amniotic fluid for endogenous TIMPs thereby providing a processed amniotic fluid having a TIMPs concentration selected from the group consisting of 10% w/v, 20% w/v, 30% w/v, 40% w/v, 50% w/v, 60% w/v, 70% w/v, 80% w/v, 90% w/v, 95% w/v and 99% w/v.

16. A method of lubricating an osteoarthritic joint in a subject in need thereof, wherein the osteoarthritis of the joint is associated with degradation of articular cartilage by proteases, the method comprising injecting into the joint a composition comprising an amniotic fluid comprising a therapeutically effective amount of tissue inhibitors of matrix metalloproteinases, thereby lubricating the osteoarthritic joint wherein the amniotic fluid is obtained from a pregnant female donor between week 28and week 37of gestation, wherein particulate matter in the amniotic fluid is substantially eliminated in the amniotic fluid prior to the composition being injected into the joint, and wherein a concentration of the tissue inhibitors of matrix metalloproteinases in a sample of the amniotic fluid is determined prior to injecting the composition into the joint, the concentration being about 10% w/v to about 100% w/v.

17. The method according to claim 16 , wherein the subject is in need of joint lubrication to provide pain-free joint movement.

18. A method of treating a joint disease, disorder, or condition in a subject in need thereof, the method comprising obtaining amniotic fluid from a female donor at the time the female donor undergoes a Caesarean section delivery procedure, testing a sample of the amniotic fluid to determine a concentration of tissue inhibitors of matrix metalloproteinases (TIMPs) in the amniotic fluid, determining whether the amniotic fluid includes a therapeutically effective amount of TIMPs based upon the concentration of TIMPs in the amniotic fluid, minimizing particulate matter in the amniotic fluid, producing a composition from the amniotic fluid, and injecting the composition comprising a therapeutically effective amount of tissue inhibitors of TIMPs into the joint of the subject, thereby treating the joint disease, disorder, or condition, wherein, when it is determined that the amniotic fluid does not include the therapeutically effective amount of TIMPs, increasing the concentration of TIMPs in the amniotic fluid.

19. The method according to claim 18 , wherein the joint is a synovial joint and the joint disease, disorder, or condition is osteoarthritis.

20. The method according to claim 18 , including adding recombinantly produced TIMPs to the amniotic fluid.